The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
Douglas L. Boggs(Yale University), Mohini Ranganathan(Yale University), Andrew Davies(GW Pharmaceuticals (United Kingdom)), Brian Pittman(Yale University), Mark J. Niciu(National Institute of Mental Health), Deepak Cyril D’Souza(Yale University), Toral Surti(Yale University), Swapnil Gupta(Yale University), Halle Thurnauer(Yale University), Aarti Gupta(Yale University), Ashley M. Schnakenberg Martin(Yale University)
Cited by 235
Related Papers
Imaging robust microglial activation after lipopolysaccharide administration in humans with PET
|Proceedings of the National Academy of Sciences|2015|349
Multimodal Neuroimaging of Frontolimbic Structure and Function Associated With Suicide Attempts in Adolescents and Young Adults With Bipolar Disorder
|American Journal of Psychiatry|2017|242
Phenethyl Isothiocyanate and Sulforaphane and their <i>N</i>-Acetylcysteine Conjugates Inhibit Malignant Progression of Lung Adenomas Induced by Tobacco Carcinogens in A/J Mice
|Cancer Research|2005|240
The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects
|Neuropsychopharmacology|2018|226
Investigating the behavioral and self-report constructs of impulsivity domains using principal component analysis
|Behavioural Pharmacology|2009|215